Marietta Investment Partners LLC Has $936,000 Stock Position in IDEXX Laboratories, Inc. $IDXX

Marietta Investment Partners LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 185.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,383 shares of the company’s stock after buying an additional 898 shares during the quarter. Marietta Investment Partners LLC’s holdings in IDEXX Laboratories were worth $936,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $29,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares during the period. Wormser Freres Gestion lifted its position in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 47 shares during the period. Finally, WealthCollab LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $560.73 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The company has a market capitalization of $44.23 billion, a PE ratio of 41.29, a price-to-earnings-growth ratio of 3.20 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98. The business has a 50 day simple moving average of $563.43 and a 200 day simple moving average of $633.51.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analyst Ratings Changes

IDXX has been the subject of a number of research reports. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Citigroup initiated coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Piper Sandler reduced their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.